AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

May 31, 2013

Study Completion Date

June 30, 2015

Conditions
Pancreatic AdenocarcinomaPancreatic Cancer
Interventions
BIOLOGICAL

AdV-tk

Four dose levels of AdV-tk with a fixed dose level of valacyclovir are evaluated independently in the two arms of the study due to differences in the concomitant standard of care treatments. The first AdV-tk course is given prior to surgery or radiation by CT or EUS guided injection into the tumor followed by 14 days of valacyclovir. The second AdV-tk injection is into the tumor bed at the time of surgery in Arm A or same as the first injection in Arm B again followed by 14 days of valacyclovir. The AdV-tk dose levels are: Level 1= 3x10e10 vector particles (vp), Level 2= 1x10e11 vp, Level 3= 3x10e11 vp, Level 4= 1x10e12 vp

DRUG

Valacyclovir

Valacyclovir caplets at a dose of 2 grams orally three times per day is administered for 14 days starting 1-3 days after each of the two AdV-tk injections in both arms.

Trial Locations (3)

43210

The Ohio State University, Columbus

91010

City of Hope Medical Center, Duarte

92037

Scripps Green Hospital/Scripps Cancer Center, La Jolla

Sponsors
All Listed Sponsors
lead

Candel Therapeutics, Inc.

INDUSTRY